Letter: increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than IBD.

Icon for Wiley Related Articles

Letter: increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than IBD.

Aliment Pharmacol Ther. 2019 Oct;50(7):834-835

Authors: Dai C, Jiang M, Sun MJ

PMID: 31532556 [PubMed – in process]

PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31532556?dopt=Abstract